“The acquisition of Turning Point Therapeutics further broadens our leading oncology franchise by adding a best-in-class, late-stage precision oncology asset,” said Giovanni Caforio, M.D., Board Chair and Chief Executive Officer, Bristol Myers Squibb.
Is Bristol-Myers a good investment?
Valuation metrics show that Bristol Myers Squibb Company may be undervalued. Its Value Score of A indicates it would be a good pick for value investors. The financial health and growth prospects of BMY, demonstrate its potential to outperform the market. It currently has a Growth Score of C.
What does turning point Therapeutics do?
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies.
What drugs does Bristol Myers Squibb make?
Our medicines
- ABECMA® (idecabtagene vicleucel)
- ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound)
- AZACTAM® (aztreonam for injection, USP)
- BREYANZI® (lisocabtagene maraleucel)
- BARACLUDE® (entecavir)
- CAMZYOSTM (mavacamten)
- DROXIA® (hydroxyurea)
- ELIQUIS® (apixaban)
Why did BMY stock drop?
Bristol Myers Squibb stock (NYSE: BMY) was down 6% in yesterday’s trade, while it’s down around 10% in a month. The recent fall can be attributed to the AXIOMATIC MATIC +11.8% -SSP study of Milvexian, which failed to achieve the primary endpoint.
Is BMY a buy sell or hold?
Out of 11 analysts, 3 (27.27%) are recommending BMY as a Strong Buy, 1 (9.09%) are recommending BMY as a Buy, 6 (54.55%) are recommending BMY as a Hold, 0 (0%) are recommending BMY as a Sell, and 1 (9.09%) are recommending BMY as a Strong Sell.
Will BMY stock go up?
Stock Price Forecast
The 17 analysts offering 12-month price forecasts for Bristol-Myers Squibb Co have a median target of 83.00, with a high estimate of 90.00 and a low estimate of 60.00. The median estimate represents a +9.33% increase from the last price of 75.92.
How does turning point make money?
Turning Point USA receives funding from a cohort of conservative and right-wing donors and foundations, including several Republican politicians. According to the Center for Media and Democracy, donors include: Marcus Foundation (Bernard Marcus): $1,573,000 in 2015–18.
Who bought turning point?
Bristol Myers Squibb
NEW YORK–(BUSINESS WIRE)– Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of Turning Point Therapeutics, Inc. (“Turning Point”), in an all-cash transaction.
How many employees does turning point therapeutics have?
142 employees
Turning Point Therapeutics is a small pharmaceutical company based in San Diego, CA with only 142 employees and an annual revenue of $25.0M. To bring differentiated therapies to patients with cancer as rapidly as possible. Turning Point’s culture unifies our team and is rooted in four core values: human Centric.
Is Bristol Myers a big pharma?
Headquartered in New York City, BMS is one of the world’s largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2021, it had a total revenue of $46.4 billion.
What is BMS famous for?
The company is known for biological and pharmaceutical research, producing the antipsychotic Abilify (which it helps market) and its blood thinners Plavix and Eliquis, as well as cancer drug Opdivo.
What drugs are Bristol Myers best known for today?
Blood cancer drug Revlimid has been Bristol-Myers’ top-selling drug, bringing in $12.8 billion in sales in 2021. But Revlimid will be facing mounting competition in the next several years. Bristol-Myers granted several companies volume-limited licenses to sell generics within the U.S. starting in March.
What is the target price for BMY stock?
Stock Price Target
| High | $90.00 |
|---|---|
| Low | $60.00 |
| Average | $80.46 |
| Current Price | $79.38 |
How often does Bristol Myers pay dividends?
There are typically 4 dividends per year (excluding specials), and the dividend cover is approximately 1.4.
What months does BMY pay dividends?
Bristol Myers’s next quarterly payment date is on Oct 31, 2022, when Bristol Myers shareholders who owned BMY shares before Oct 05, 2022 received a dividend payment of $0.54 per share. Add BMY to your watchlist to be reminded of BMY’s next dividend payment.
Does BMY stock pay a dividend?
Ratings – BMY
Stable. 2.75% forward dividend yield. Bottom 50%.
Does BMY have a dividend?
Historical dividend payout and yield for Bristol Myers Squibb (BMY) since 1990. The current TTM dividend payout for Bristol Myers Squibb (BMY) as of October 27, 2022 is $2.16. The current dividend yield for Bristol Myers Squibb as of October 27, 2022 is 2.97%.
How much debt is BMY?
Bristol Myers Squibb long term debt for 2020 was $48.336B, a 11.41% increase from 2019. Bristol Myers Squibb long term debt for 2019 was $43.387B, a 668.46% increase from 2018.
Compare BMY With Other Stocks.
| Bristol Myers Squibb Annual Long Term Debt (Millions of US $) | |
|---|---|
| 2009 | $6,130 |
Does Astrazeneca own Bristol-Myers Squibb?
Over time, AstraZeneca will also become responsible for the manufacturing and supply chain of the full portfolio of diabetes products.
AstraZeneca to acquire Bristol-Myers Squibb share of global diabetes alliance assets.
| Media Enquiries | ||
|---|---|---|
| Media EnquiriesAyesha Bharmal | (UK/Global) | +44 20 7604 8034 |
Is DOYU a good buy?
Its Value Score of B indicates it would be a good pick for value investors. The financial health and growth prospects of DOYU, demonstrate its potential to outperform the market.